hrcak mascot   Srce   HID

Review article


Davor Miličić
Boško Skorić

Fulltext: croatian, pdf (240 KB) pages 0-0 downloads: 502* cite
APA 6th Edition
Miličić, D. & Skorić, B. (2011). ASPIRINSKA REZISTENCIJA. Liječnički vjesnik, 133 (9-10), 0-0. Retrieved from
MLA 8th Edition
Miličić, Davor and Boško Skorić. "ASPIRINSKA REZISTENCIJA." Liječnički vjesnik, vol. 133, no. 9-10, 2011, pp. 0-0. Accessed 24 Oct. 2020.
Chicago 17th Edition
Miličić, Davor and Boško Skorić. "ASPIRINSKA REZISTENCIJA." Liječnički vjesnik 133, no. 9-10 (2011): 0-0.
Miličić, D., and Skorić, B. (2011). 'ASPIRINSKA REZISTENCIJA', Liječnički vjesnik, 133(9-10), pp. 0-0. Available at: (Accessed 24 October 2020)
Miličić D, Skorić B. ASPIRINSKA REZISTENCIJA. Liječnički vjesnik [Internet]. 2011 [cited 2020 October 24];133(9-10):0-0. Available from:
D. Miličić and B. Skorić, "ASPIRINSKA REZISTENCIJA", Liječnički vjesnik, vol.133, no. 9-10, pp. 0-0, 2011. [Online]. Available: [Accessed: 24 October 2020]

Although present in pharmacotherapy for more than 100 years, aspirin still represents a cornerstone in the primary and secondary prevention of cardiovascular patients. Despite undoubtful benefit, a certain proportion of patients treated with aspirin develops adverse atherothrombotic events like stent thrombosis, myocardial infarction, stroke and cardiovascular death. In recent years, there is a growing scientific interest concerning the relationship of suboptimal antiplatelet response to aspirin and cardiovascular prognosis that has led to the concept of »aspirin resistance«. Besides the absence of uniform definition of aspirin resistance, an important issue in these studies are numerous and poorly standardized laboratory methods that are used in its detection. Despite an increasing number of reports that favour its clinical significance, there are still no expert recommendations for routine assessment of platelet aggregation as well as for modification of antiplatelet doses or regimens in the case of established aspirin resistance.

Aspirin – therapeutic use, pharmacology; Drug resistance; Platelet aggregation inhibitors – therapeutic use, pharmacology; Cyclooxygenase inhibitors – therapeutic use; Blood platelets – drug effects, physiology; Platelet function tests – methods; Cardiovascular diseases – drug therapy, complications; Thrombosis – prevention and control

Hrčak ID: 171855



Visits: 618 *